Rapid Communication
Copyright ©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Aug 14, 2007; 13(30): 4103-4107
Published online Aug 14, 2007. doi: 10.3748/wjg.v13.i30.4103
Table 1 Demographic data
CharacteristicHD-03/ES
Age (yr)Mean (SD)33.7 (6.6)
Median (range)36 (20-45)
SexMale22
Female3
Body weight (kg)Mean (SD)56 (10)
Table 2 Effect of six months treatment with HD-03/ES on liver function tests (mean ± SD)
Parameterd 0Four monthsSix months
Alanine aminotransferase (ALT) (IU/L)66.5 ± 11.141.6 ± 05.139.1 ± 5.2
Aspartate aminotransferase (AST) (IU/L)47.5 ± 9.542.4 ± 10.740.2 ± 10.1
Serum albumin (g%)3.5 ± 0.83.5 ± 0.73.6 ± 0.7
Serum globulin (g%)2.9 ± 0.33.1 ± 0.23.2 ± 0.2
Total protein (g%)6.2 ± 0.76.5 ± 0.76.5 ± 0.7
Serum bilirubin (mg%)1.3 ± 0.61.2 ± 0.51.1 ± 0.5
Alkaline phosphatase (IU/L)155.5 ± 9.8140.2 ± 9.0127.0 ± 7.5
Table 3 Biochemical and serological response to 6 mo of HD-03/ES therapy
VariableHD-03/ES (No. of patients)
ALT normalization (%)Four months32%
Six months56%
PositiveNegative
HBsAgd 0250
Four months196
Six months1213b
HBeAg
d 0169
Four months1114
Six months1015a
HBV DNAd 0169
Four months1114
Six months1015a
Table 4 List of adverse effects
Adverse effectHD-03/ES
Abdominal discomfort3
Fatigue2
Headache1
Insomnia1